button bars forest bayes pooled summary circles
 
deaths (OS)

mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - all population

mNSCLC - L1 - PDL1 negative metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 negative

mNSCLC - L1 - PDL1 positive metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - PDL1 positive

versus Standard of Care (SoC)
atezolizumab alone vs. Standard of Care (SoC) 3 0.83 [0.65; 1.06], 1 RCT, I2=0%
inconclusive result

mNSCLC - L1 - TMB>10Mb metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) mNSCLC - L1 - TMB10Mb

non squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - all population

versus atezolizumab plus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. atezolizumab plus carboplatin plus nab-paclitaxel 1 0.80 [0.65; 0.99], 1 RCT, I2=0% conclusive
unassessable degree of certainty
versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 0.76 [0.63; 0.92], 1 RCT, I2=0%
unassessable degree of certainty
atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 1 0.85 [0.71; 1.02], 1 RCT, I2=0%
inconclusive result

non squamous - mNSCLC - L1 - Wild Type (WT) metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) non squamous cell - mNSCLC - L1 non squamous - mNSCLC - L1 - Wild Type (WT)

versus bevacizumab plus carboplatin and paclitaxel
atezolizumab plus bevacizumab plus carboplatin plus paclitaxel vs. bevacizumab plus carboplatin and paclitaxel 2 0.78 [0.64; 0.96], 1 RCT, I2=0% conclusive
unassessable degree of certainty
versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 0.79 [0.64; 0.98], 1 RCT, I2=0% conclusive
unassessable degree of certainty
versus pemetrexed plus platin
atezolizumab plus pemetrexed and platin vs. pemetrexed plus platin 1 0.81 [0.64; 1.03], 1 RCT, I2=0%
inconclusive result

squamous - mNSCLC - L1 - all population metastatic/advanced NSCLC (mNSCLC) - 1st line (L1) squamous cell - mNSCLC - L1 squamous - mNSCLC - L1 - all population

versus carboplatin plus nab-paclitaxel
atezolizumab plus carboplatin plus nab-paclitaxel vs. carboplatin plus nab-paclitaxel 1 0.88 [0.73; 1.06], 1 RCT, I2=0%
inconclusive result

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons